Femasys Inc
FEMY0.810USD
-0.010-1.18%
Horário de mercado （ET）Cotações atrasadas em 15 min
21.94MValor de mercado
PerdaP/L TTM
Mais detalhes de Femasys Inc Empresa
Femasys Inc. is a biomedical company. The Company is focused on addressing unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
Informações da empresa
Código da empresaFEMY
Nome da EmpresaFemasys Inc
Data de listagemJun 18, 2021
CEOMs. Kathy Lee-Sepsick
Número de funcionários69
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 18
Endereço3950 Johns Creek Court
CidadeSUWANEE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal30024
Telefone17705003910
Sitehttps://www.femasys.com/
Código da empresaFEMY
Data de listagemJun 18, 2021
CEOMs. Kathy Lee-Sepsick
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
384.31K
+9.80%
Mr. Alistair Milnes
Mr. Alistair Milnes
Independent Director
Independent Director
5.67K
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
80.00
--
Mr. Dov Elefant
Mr. Dov Elefant
Chief Financial Officer
Chief Financial Officer
--
--
Dr. James Liu, M.D.
Dr. James Liu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles E. Larsen
Mr. Charles E. Larsen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Independent Director
Independent Director
--
--
Mr. Daniel Currie
Mr. Daniel Currie
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Edward Uzialko, Jr.
Mr. Edward Uzialko, Jr.
Independent Director
Independent Director
--
--
Ms. Christine Thomas
Ms. Christine Thomas
Chief Regulatory and Clinical Officer
Chief Regulatory and Clinical Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
384.31K
+9.80%
Mr. Alistair Milnes
Mr. Alistair Milnes
Independent Director
Independent Director
5.67K
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
80.00
--
Mr. Dov Elefant
Mr. Dov Elefant
Chief Financial Officer
Chief Financial Officer
--
--
Dr. James Liu, M.D.
Dr. James Liu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles E. Larsen
Mr. Charles E. Larsen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Detalhamento da receita
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
341.26K
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 18 de jul
Atualizado em: sex, 18 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Chernett (Jorey)
4.99%
Dauntless Investment Group, LLC
4.84%
Uzialko (Edward R Jr.)
3.74%
The Vanguard Group, Inc.
2.54%
CM Management, LLC
1.31%
Other
82.58%
Investidores
Investidores
Proporção
Chernett (Jorey)
4.99%
Dauntless Investment Group, LLC
4.84%
Uzialko (Edward R Jr.)
3.74%
The Vanguard Group, Inc.
2.54%
CM Management, LLC
1.31%
Other
82.58%
Tipos de investidores
Investidores
Proporção
Individual Investor
10.52%
Investment Advisor
10.24%
Investment Advisor/Hedge Fund
1.26%
Hedge Fund
0.23%
Venture Capital
0.10%
Research Firm
0.09%
Bank and Trust
0.05%
Other
77.52%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
70
7.31M
22.48%
+821.23K
2025Q1
67
7.22M
24.70%
+706.34K
2024Q4
60
4.03M
17.61%
-312.38K
2024Q3
58
3.32M
14.71%
-994.98K
2024Q2
60
3.27M
14.50%
-951.60K
2024Q1
59
3.16M
17.88%
-1.13M
2023Q4
59
3.12M
17.80%
-765.84K
2023Q3
57
3.89M
25.74%
+6.18K
2023Q2
54
3.49M
25.26%
-520.59K
2023Q1
51
3.40M
28.73%
-4.68M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Chernett (Jorey)
1.62M
4.99%
+1.62M
--
Feb 19, 2025
Dauntless Investment Group, LLC
1.58M
4.84%
+145.30K
+10.16%
Mar 31, 2025
Uzialko (Edward R Jr.)
1.22M
3.74%
--
--
Apr 08, 2025
The Vanguard Group, Inc.
825.67K
2.54%
--
--
Mar 31, 2025
CM Management, LLC
425.00K
1.31%
--
--
Mar 31, 2025
Lee-Sepsick (Kathy)
384.31K
1.18%
+34.31K
+9.80%
Jun 02, 2025
Clear Creek Financial Management, LLC
270.37K
0.83%
+14.00K
+5.46%
Mar 31, 2025
Geode Capital Management, L.L.C.
245.51K
0.75%
+29.34K
+13.57%
Mar 31, 2025
Currie (Daniel Scott)
109.24K
0.34%
+19.61K
+21.88%
Jun 02, 2025
State Street Global Advisors (US)
56.37K
0.17%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
